Abstracts tagged "psoriasis"

Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 2542 • 2017 ACR/ARHP Annual Meeting
Measuring Psoriasis Specific Impact on Quality of Life: Performance of Dlqi and Skindex-17 in Early Psoriatic Arthritis
Kim Wervers¹, Jolanda J. Luime², Ilja Tchetverikov³, Andreas H. Gerards⁴, Marc R Kok⁵, Cathelijne W. Y. Appels⁶, Wiebo L. van der Graaff⁷, Johannes H. L. M. van Groenendael⁸, Lindy-Anne Korswagen⁹, Jozien Veris¹⁰, J.M.W. Hazes² and Marijn Vis², ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Sint Franciscus Vlietland Group, Schiedam, Netherlands, ⁵Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Rheumatology, Amphia Hospital, Breda, Netherlands, ⁷Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ¹⁰Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: Impact of dermatological disease is measured with the Dermatology Life Quality Index (DLQI) and Skindex-17. DLQI is commonly used in dermatology trials but the…
Abstract Number: 2556 • 2017 ACR/ARHP Annual Meeting
Were Moll and Wright Right?
Sergio Schwartzman¹, Madeline Epsten², Jackie Szymonifka², Stephen A. Paget³ and Lisa A. Mandl¹, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: In 1973 Moll and Wright published the first paper on the classification criteria for Psoriatic Arthritis (PsA). In their pioneering work, these authors additionally…
Abstract Number: 2557 • 2017 ACR/ARHP Annual Meeting
Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not?
Vivian G. Szeto^1,2, Justine Y. Ye¹, Vinod Chandran³, Dafna D Gladman⁴ and Cheryl F. Rosen⁵, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of people with psoriasis. The current understanding of these diseases involves patients who…
Abstract Number: 624 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial
Philip S. Helliwell¹, Eric Lespessailles², Catherine Shuler³, Lotus Mallbris³, Janelle Erickson³ and Roy Fleischmann⁴, ¹St. Luke's Hospital and University of Leeds, Bradford, United Kingdom, ²University Orleans, Orleans, France, ³Eli Lilly and Company, Indianapolis, IN, ⁴Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. In the SPIRIT-P1 phase 3 study (NCT01695239), IXE was superior to placebo…
Abstract Number: 2969 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Mark C. Genovese¹, Bernard Combe², Joel Kremer³, David Adams⁴, Chin Lee⁴, Lisa Kerr⁴ and Peter Nash⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³St. Peter's Hospital, Albany, NY, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In patients with active psoriatic arthritis (PsA) who had an inadequate response…
Abstract Number: 625 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials
Atul A. Deodhar¹, Kim A. Papp², Catherine Shuler³, So Young Park³ and Tore K. Kvien⁴, ¹Oregon Health & Science University, Portland, OR, ²K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rapid onset of clinical improvement is an important attribute of treatment success for patients with PsA. These analyses evaluate the speed of onset of…
Abstract Number: 639 • 2017 ACR/ARHP Annual Meeting
Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort
Andrea Cuervo¹, Julio Ramírez², Merce Alsina³, Raimon Sanmarti⁴ and Juan D. Cañete⁵, ¹Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ²Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Dermatology Dpt, Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Arthritis Unit. Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Early diagnosis in psoriatic arthritis (PsA) is mandatory in order to initiate early therapy and prevent disability. Around 20% of patients with Psoriasis (PsO)…
Abstract Number: 882 • 2017 ACR/ARHP Annual Meeting
A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients
Keith Colaco^1,2, Dana Jerome³, Jensen Yeung^4,5, Noah Ivers^6,7,8, Carol Kitai⁷, Chandra Farrer³ and Lihi Eder^1,9, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Women's College Hospital, Toronto, ON, Canada, ⁴Dermatology, Women's College Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada, ⁸Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients is high, with delays in diagnosis contributing to poor patient outcomes. We aimed to…
Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Jeffrey A. Sparks¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Natsumi Ikumi¹, Agnes Szentpetery¹, Brian Kirby² and Oliver FitzGerald¹, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 1726 • 2016 ACR/ARHP Annual Meeting
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Lianne S. Gensler¹, Elizabeth C. Hsia², Christopher Gasink², Bruce Randazzo², Dennis Parenti³, Steve Fakharzadeh³, Kehzen L. Tang² and Soumya Chakravarty³, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Objective:Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in…
Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting
Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Kim Papp¹, Alice B. Gottlieb², Catherine L. Shuler³, Russel T. Burge³, Gregory Cameron³, Lisa Kerr³ and Philip J Mease⁴, ¹K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ²Tufts University School of Medicine, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 2170 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk in Patients with Psoriasis, Psoriatic and Rheumatoid Arthritis: A Prospective Study Using Secured Anonymised Information Technology Databank in Wales, United Kingdom
Ernest H. Choy¹, Roxanne Cooksey², Sinead Brophy², Jonathan Kennedy², Fabiola Fernandez-Gutierrez³, Ruth Davies⁴, Timothy Pickles⁵ and Vincent Piguet⁶, ¹CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ²College of Medicine, Swansea University, Swansea, United Kingdom, ³Cancer Research UK Manchester Institute, Manchester, United Kingdom, ⁴CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ⁵CREATE Center, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ⁶Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Compared with cardiovascular (CV) risk in rheumatoid arthritis (RA), precise CV risk in psoriatic arthritis (PsA) and psoriasis is less established, particularly the relative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.